Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463822 · ClinicalTrials.gov registry record · Early Phase 1
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT05463822: Completed Early Phase 1 study, sponsored by Stanford University.
NCT05463822 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463822, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope inserted into the bladder which can be painful and is associated with a risk of urinary tract infection. The purpose of this study is to determine if transvaginal injection of BTA into the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the treatment of refractory overactive bladder.
Interventions
- DRUG Transvaginal botulinum toxin A (BTA) injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2021-09-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05463822
The ClinicalTrials.gov registry entry for NCT05463822 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transvaginal botulinum toxin A (BTA) injection is the first listed.
NCT05463822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05463822 about?
NCT05463822 is a clinical study titled "Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder". Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope inserted into the bl...
What is the current status of trial NCT05463822?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2019-06-20. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT05463822?
The interventions under investigation include: Transvaginal botulinum toxin A (BTA) injection (DRUG).
Who is sponsoring clinical trial NCT05463822?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.